Zacks Research Analysts Boost Earnings Estimates for COO
Zacks Research analysts have increased their Q3 2027 earnings estimates for Cooper Companies (NASDAQ: COO) to $1.25 per share, up from $1.24, and have also lifted several full-year and quarterly forecasts. This indicates improved analyst expectations for the medical device company's margins and earnings momentum. Cooper Companies recently surpassed earnings estimates and reported positive revenue growth, with current Street ratings maintaining a "Moderate Buy" consensus despite warnings of potential Asia-market softness and geopolitical risks.
COO SEC Filings - Cooper 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of CooperCompanies (COO) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports (Form 4). It highlights recent insider transactions by executives and directors, detailing RSU vestings, stock purchases, and charitable gifts. The platform also offers AI-powered summaries to help investors understand these regulatory documents more efficiently.
ALGN (Align Technology) Net Change in Cash : $51 Mil (TTM As of Dec. 2025)
Align Technology (ALGN) recorded a Net Change in Cash of $51 million for the trailing twelve months (TTM) ended December 2025, and $90 million for the quarter ended December 2025. GuruFocus assesses ALGN with a GF Score of 89/100 and a GF Value of $249.91, indicating it is significantly undervalued compared to its current price of $166.38, despite having six warning signs for investors. The article details the calculation of Net Change in Cash and provides historical data and comparisons for the company.
Reasons to Consider Including Cooper Companies Shares in Your Investment Portfolio Today
Cooper Companies (COO) is experiencing growth due to CooperVision's premium lenses and myopia management and CooperSurgical's women's health and fertility portfolio. Despite short-term challenges like Asia-Pacific weakness and geopolitical risks, the company maintains a strong competitive edge, boasts improving margins through efficiency, and benefits from a recovering fertility market. Analysts project increased revenues and EPS for fiscal 2026, with the stock currently holding a Zacks Rank #2 (Buy).
Reasons to Add Cooper Companies Stock to Your Portfolio Now
The Cooper Companies (COO) is recommended as a Zacks Rank #2 (Buy) stock due to its market share gains, premium product momentum in CooperVision, and strong margin expansion driven by operational efficiencies and AI adoption. CooperSurgical's growth is also supported by recovery trends in the fertility market. Despite challenges like Asia-Pacific weakness and geopolitical risks, the company's long-term opportunities are strong.
Reasons to Add Cooper Companies Stock to Your Portfolio Now
The Cooper Companies (COO) is positioned for growth due to the success of its CooperVision premium lens migration and MiSight's myopia management, alongside CooperSurgical's women's health portfolio. While facing near-term challenges like Asia-Pacific weakness and geopolitical risks affecting its fertility segment, the company shows strong long-term potential fueled by market share gains, operational efficiencies, and recovery in the fertility market. Analysts project a 5.5% revenue growth and 11.7% adjusted EPS improvement for fiscal 2026.
Zacks Research Analysts Boost Earnings Estimates for COO
Zacks Research has upgraded its earnings estimates for The Cooper Companies (COO) for Q2 2026, FY2026, FY2027, and FY2028, signaling stronger future financial performance. The medical device company recently beat Q4 earnings and revenue consensus estimates and provided optimistic Q2 2026 guidance. Analysts generally have a "Moderate Buy" rating for COO, with institutional investors holding a significant portion of its stock.
Assenagon Asset Management S.A. Grows Position in The Cooper Companies, Inc. $COO
Assenagon Asset Management S.A. significantly increased its stake in The Cooper Companies (NASDAQ: COO) by 4,342.5% in Q4, acquiring 265,198 additional shares to hold a total of 271,305 shares valued at $22.24 million. This move is supported by Cooper Companies' strong Q4 performance, beating EPS and revenue expectations, and a "Moderate Buy" consensus rating from analysts with an average price target of $90.79. The medical device company currently has a market capitalization of $13.96 billion and institutional investors own 24.39% of its stock.
CooperCompanies Stock: Steady Growth in Medical Devices Amid Market Challenges for North American Investors
The Cooper Companies (NASDAQ:COO) is highlighted as a resilient player in the medical device sector, particularly in vision care and surgical solutions, noting stable revenue growth and raised guidance. Despite a 20% year-to-date share price drop, the company's strong financial performance, strategic investments in R&D, and significant share repurchase program make it an attractive option for conservative North American investors seeking stability in healthcare. Analysts rate the stock as a "Moderate Buy" with an average price target implying a 15% upside.
COO SEC Filings - Cooper 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Cooper (COO) SEC filings, including 10-K, 10-Q, and 8-K forms, detailing its operations as a global medical device company through CooperVision and CooperSurgical. It offers real-time updates and AI-powered summaries to help investors understand financial performance, governance, and insider trading activities. Recent filings cover executive equity awards, insider purchases, and Q3 2025 results, which noted gross margin pressure and an IT control weakness.
Therapy animals will reach 100,000 patients and care teams in pilot
Pet Partners and the Baxter Foundation (NYSE: BAX) have launched a two-year pilot program to expand therapy animal visits, aiming to reach 100,000 patients and healthcare workers in three key U.S. regions. This initiative seeks to reduce stress and improve resilience by providing resources, training, and volunteer support, building on the proven benefits of human-animal interaction in healthcare settings. The program also includes research to further understand the impact of therapy animals on healthcare professionals and offers engagement opportunities for Baxter employees.
Here's Why The Cooper Companies (COO) is a Strong Value Stock
The article, sourced from Zacks Investment Research, highlights why The Cooper Companies (COO) is considered a strong value stock. It encourages readers to get the latest recommendations from Zacks, including a free report on "7 Best Stocks for the Next 30 Days."
Here's Why The Cooper Companies (COO) is a Strong Value Stock
This article from Zacks Equity Research highlights The Cooper Companies (COO) as a strong value stock. It mentions that investors looking for such opportunities can download a free report on "7 Best Stocks for the Next 30 Days" from Zacks Investment Research, and encourages further analysis of COO's stock.
Congress Asset Management Co. Sells 219,394 Shares of The Cooper Companies, Inc. $COO
Congress Asset Management Co. reduced its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 48.5% during the fourth quarter, selling 219,394 shares and holding 232,899 shares valued at approximately $19.09 million. Despite this sale, Cooper Companies recently beat Q1 EPS expectations, reporting $1.10 per share against a $1.03 consensus, and provided strong Q2 2026 EPS guidance. Analysts maintain a "Moderate Buy" rating with an average target of $90.79, although the stock is currently trading below its 50- and 200-day moving averages suggesting potential technical headwinds.
3 Reasons Why Growth Investors Shouldn't Overlook The Cooper Companies (COO)
The Cooper Companies (COO) is identified as a strong growth stock due to its favorable Zacks Growth Style Score and top Zacks Rank. Key factors include projected double-digit earnings growth (11.7% this year), robust cash flow growth (7.9% year-over-year), and positive trends in earnings estimate revisions. These elements position COO for potential outperformance for growth investors.
Barclays Maintains Cooper Companies(COO.US) With Buy Rating, Maintains Target Price $103
Barclays has reiterated its 'Buy' rating on Cooper Companies (COO.US) and maintained its target price at $103. This indicates a continued positive outlook from the firm regarding Cooper Companies' stock performance.
Swiss Life Asset Management Ltd Buys 19,264 Shares of The Cooper Companies, Inc. $COO
Swiss Life Asset Management Ltd increased its stake in The Cooper Companies (NASDAQ:COO) by 63.9% in Q3, purchasing an additional 19,264 shares, bringing its total holdings to 49,409 shares valued at $3.387 million. The Cooper Companies recently exceeded Q1 earnings expectations and provided strong Q2 2026 EPS guidance, while analysts maintain a "Moderate Buy" consensus rating with a target price of $90.79. Several other hedge funds have also adjusted their positions in COO, indicating continued institutional interest in the medical device company.
FDA expands approval for Staar Surgical's popular implantable lens
Staar Surgical has received expanded FDA approval for its EVO/EVO+ Visian ICL (implantable collamer lens) to include adults with hyperopia, or farsightedness. This approval allows the lens to treat a wider range of refractive errors, potentially increasing its market reach and benefitting more patients seeking vision correction.
Cooper Companies cut to Equal Weight at Wells Fargo on segment challenges
Wells Fargo has downgraded Cooper Companies to Equal Weight, citing concerns about challenges in its CooperVision segment and other factors. The financial institution reduced its price target for the company from $120 to $105 per share. This downgrade reflects a more cautious outlook on Cooper Companies' near-term performance.
Alcon and Lensar terminate proposed merger after FTC pressure
Alcon and LENSAR have terminated their proposed merger agreement, nearly a year after its announcement, due to pressure from the Federal Trade Commission (FTC). The FTC opposed the deal, citing concerns that it would reduce competition, increase prices, and stifle innovation in the femtosecond laser-assisted cataract surgery (FLACS) market. This marks the second merger Alcon has attempted and terminated recently, with LENSAR now focusing on expanding its ALLY System and seeking alternative investors.
Is Hologic Stock Outperforming the Dow?
Hologic, Inc. (HOLX) has outperformed the Dow Jones Industrials Average ($DOWI) over the past three months, year-to-date, and over the past 52 weeks, despite a recent dip after Q1 2026 results. The company's stock has risen marginally in these periods while the Dow has seen decreases or lesser returns. Analysts, however, maintain a "Hold" rating on HOLX with a mean price target suggesting only a marginal premium.
The Cooper Companies, Inc. $COO Shares Sold by JPMorgan Chase & Co.
JPMorgan Chase & Co. significantly reduced its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 48.9% in the third quarter, selling 1,318,798 shares and retaining 1,376,493 shares worth $94,372,000. Despite this, other institutional investors either increased their holdings or maintained them, with 24.39% of the stock owned by hedge funds and institutional investors overall. The article also provides a company profile, recent stock performance metrics, earnings data, and details on insider transactions including share acquisitions by directors.
Is Cooper Companies Stock Underperforming the Dow?
Cooper Companies (COO) stock has been underperforming the Dow Jones Industrials Average and its peer, Align Technology, Inc. (ALGN). COO's stock is down 20.9% from its 52-week high, declined 12.3% over the past three months, and 12.5% over the past year, while the DOWI gained 13.2% in the last year. Despite mixed Q1 2026 earnings, analysts have a "Moderate Buy" rating with a 27.8% upside potential.
Is Cooper Companies Stock Underperforming the Dow?
The Cooper Companies, Inc. (COO) has a market capitalization of $13.9 billion, but its stock has seen a significant decline, falling 20.9% from its 52-week high and 12.3% over the past three months. This underperformance contrasts sharply with the Dow Jones Industrials Average ($DOWI), which gained 13.2% over the past year. COO's recent Q1 2026 earnings showed mixed results, with revenue meeting estimates and EPS beating them, but concerns over weak organic revenue growth and challenges in the Asia Pacific region led to a further stock drop.
Delta Global Management LP Decreases Holdings in The Cooper Companies, Inc. $COO
Delta Global Management LP significantly reduced its stake in The Cooper Companies (NASDAQ:COO) by 48.3% during the third quarter, now holding 16,386 shares valued at $1.123 million. Other institutional investors have also adjusted their holdings, with 24.39% of the stock owned by hedge funds and institutions. The company reported strong Q4 earnings, surpassing analyst estimates, and various analysts have updated their ratings and price targets for COO.
Is Cooper Companies Stock Underperforming the Dow?
The Cooper Companies, Inc. (COO) is underperforming the Dow Jones Industrials Average, with its stock down 20.9% from its 52-week high and lagging behind the DOWI's gains over the past year. This underperformance is attributed to weak organic revenue growth and slower business in the Asia Pacific region, despite beating EPS estimates in its Q1 2026 earnings. Analysts, however, maintain a "Moderate Buy" rating with a significant upside potential.
The Cooper Companies, Inc. $COO Shares Sold by Alliancebernstein L.P.
Alliancebernstein L.P. reduced its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 15.7% in the third quarter, selling 594,374 shares. Despite this, several other institutional investors acquired new stakes. The article also details recent insider purchases by directors Maria Rivas and Lawrence Erik Kurzius, analyst ratings, and the company's recent financial performance.
JANA Partners Management LP Takes $166.92 Million Position in The Cooper Companies, Inc. $COO
JANA Partners Management LP has acquired a new stake in The Cooper Companies, totaling 2,434,607 shares valued at approximately $166.92 million, making it their 5th largest holding. The Cooper Companies recently surpassed quarterly earnings expectations with an EPS of $1.10 and revenue of $1.02 billion. Despite varying analyst ratings, the stock holds a consensus "Moderate Buy" rating with an average target price of $90.79.
Kettle Hill Capital Management LLC Takes Position in The Cooper Companies, Inc. $COO
Kettle Hill Capital Management LLC recently acquired a new position in The Cooper Companies, Inc. (NASDAQ:COO), purchasing 33,773 shares valued at approximately $2.315 million. Other institutional investors also adjusted their holdings in Cooper Companies. The article also provides a performance overview of COO stock, its recent earnings, and analyst ratings, alongside details of recent insider stock purchases.
Holocene Advisors LP Trims Stock Holdings in The Cooper Companies, Inc. $COO
Holocene Advisors LP reduced its stake in The Cooper Companies (NASDAQ:COO) by 16.1% in the 3rd quarter, selling 328,977 shares. Despite this, other institutional investors like Vanguard Group Inc. and Capital World Investors increased their holdings. The stock has seen recent insider buying activity and analysts have a "Moderate Buy" consensus rating with an average target price of $90.79.
Bamco Inc. NY Reduces Stock Position in The Cooper Companies, Inc. $COO
Bamco Inc. NY significantly reduced its holdings in The Cooper Companies, Inc. by 25.4% during the third quarter, selling over 225,000 shares. Despite this reduction, institutional investors collectively own 24.39% of Cooper Companies' stock. Several analysts have adjusted their price targets and ratings for COO, with the consensus remaining a "Moderate Buy" at $90.79.
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Demand Shifts
Bausch + Lomb Corp (CA07174N1090) stock is under pressure due to margin challenges in contact lenses and surgical equipment, despite steady demand. The company faces headwinds from high costs, softer surgical performance, and macroeconomic pressures like inflation, though its core business drivers in vision care and pharmaceuticals offer some resilience. Investors are urged to monitor Q2 guidance and pipeline milestones, as the stock presents a balanced opportunity for patient capital with structural demand supporting growth.
Cooper Companies Stock Rallies on Q1 Earnings Beat and Raised Guidance as Medical Device Maker Gains
Cooper Companies (NASDAQ: COO) has reported a strong Q1 2026 earnings beat, exceeding analyst expectations and raising Q2 guidance. This performance has led to a rally in its stock, attracting significant institutional investment and causing analysts to raise price targets. The medical device maker is showing resilience in the optical health market, with its valuation becoming attractive relative to its growth prospects.
Clearline Capital LP Purchases 284,921 Shares of The Cooper Companies, Inc. $COO
Clearline Capital LP significantly increased its stake in The Cooper Companies (COO) by acquiring an additional 284,921 shares, bringing its total to 380,090 shares valued at approximately $26.06 million. This makes COO the fund's 11th largest position. Recent insider activity also shows purchases by CEO Albert G. White III and Director Cynthia L. Lucchese, totaling 16,014 shares bought in the last 90 days. The company reported better-than-expected Q1 earnings of $1.10 EPS and solid revenue, with analysts maintaining a "Moderate Buy" consensus rating.
ArrowMark Colorado Holdings LLC Acquires 299,289 Shares of The Cooper Companies, Inc. $COO
ArrowMark Colorado Holdings LLC increased its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 35.1% in the third quarter, acquiring an additional 299,289 shares. Other institutional investors also modified their holdings, and company insiders made significant stock purchases. The medical device company reported strong Q1 earnings, beating analyst estimates, and has received varied analyst ratings, resulting in an average target price of $90.79.
Five9 Earns 'Moderate Buy' Rating from Analysts
Five9, Inc. (NASDAQ:FIVN) has received a consensus "Moderate Buy" rating from 20 research firms, with an average 12-month price target of $27.12 per share. While a majority recommend buying, a mix of views from analysts reflects the competitive nature of the customer experience management software market. The company's ability to innovate and execute its cloud-based strategy will be crucial for future growth.
Why The Cooper Companies (COO) is a Top Value Stock for the Long-Term
The Cooper Companies (COO) is considered a top value stock due to its favorable valuation metrics, strong earnings outlook, and growth potential in the contact lens and fertility markets. Its PEG ratio, P/S ratio, and P/CF ratio suggest undervaluation compared to industry averages and the broader market. Analysts project significant earnings growth for the current fiscal year, making COO an attractive long-term investment.
Ossiam Has $21.39 Million Holdings in The Cooper Companies, Inc. $COO
Ossiam significantly increased its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 5,978.9% in Q3, now holding 312,028 shares valued at approximately $21.39 million. Company insiders have also recently purchased shares, with CEO Albert G. White III and a director acquiring 16,014 shares totaling around $1.30 million. Cooper Companies beat its quarterly EPS expectations and analysts currently have a "Moderate Buy" consensus rating with an average price target of $90.79.
Integral Health Asset Management LLC Acquires 25,000 Shares of The Cooper Companies, Inc. $COO
Integral Health Asset Management LLC significantly increased its stake in The Cooper Companies (NASDAQ:COO) by 35.7% in Q3, acquiring an additional 25,000 shares to bring its total holding to 95,000 shares worth $6.51 million. Company insiders also purchased shares, with CEO Albert G. White III buying 10,000 shares and director Maria Rivas buying 1,000 shares, bringing total insider acquisitions to over $1.30 million in the past 90 days. Cooper Companies recently surpassed Q1 earnings expectations, reporting $1.10 EPS against an estimated $1.03, and analysts maintain a "Moderate Buy" consensus with an average price target of $90.79.
COO Stock Falls -17% With A 9-day Losing Streak On Revenue Shock
The article reports that the COO stock has experienced a significant -17% drop, extending its losing streak to nine consecutive days. This sharp decline is attributed to a "revenue shock" that has impacted the company's financial performance.
COO Stock Falls -17% With A 9-day Losing Streak On Revenue Shock
Cooper Companies (COO) recently experienced a 9-day losing streak, resulting in a 17% stock drop and a $2.7 billion market cap reduction due to a Q1 2026 revenue miss. Despite an EPS beat, the underwhelming revenue, particularly a 4% sales decline in the Asia-Pacific region, triggered a sharp stock decline. Trefis analysts suggest the stock is unattractive given its moderate operating performance and high valuation, advising investors to look for predictive signals rather than reactive news.
Alcon Inc Stock (ISIN: CH0432492467) Holds Steady Amid Eye Care Sector Resilience
Alcon Inc. (ALC) stock is trading steadily near $76, supported by analyst optimism for a 20% upside and strategic capital returns like a $750 million buyback. The eye care leader maintains a dominant position in contact lenses and surgical products, with strong recurring revenues and a robust balance sheet. European and DACH investors find the Swiss-domiciled company attractive due to its Xetra accessibility, exposure to aging demographics, and disciplined capital allocation.
Quantitative Investment Management Boosts Stake in Cooper Companies
Quantitative Investment Management LLC significantly increased its stake in The Cooper Companies, Inc. by 111.8% in the third quarter, bringing its total holdings to 36,024 shares valued at $2,469,000. This increase suggests the institutional investor's confidence in the medical device company's performance and growth prospects. Cooper Companies is a key player in vision care and women's health markets, making institutional ownership changes a strong indicator of market sentiment.
Mackenzie Financial Corp Acquires 433,311 Shares of The Cooper Companies, Inc. $COO
Mackenzie Financial Corp has significantly increased its stake in The Cooper Companies, Inc. (NASDAQ:COO) by acquiring an additional 433,311 shares, bringing its total holdings to 513,557 shares valued at approximately $35.2 million. This increase reflects confidence in Cooper Companies, which recently surpassed quarterly EPS estimates and provided strong Q2 2026 guidance. Analyst ratings remain positive, with a consensus of "Moderate Buy" and a price target of $90.79, further supported by recent insider buying activity.
Swiss National Bank Sells 30,300 Shares of The Cooper Companies, Inc. $COO
The Swiss National Bank reduced its stake in The Cooper Companies (NASDAQ:COO) by 5.0% in the third quarter, selling 30,300 shares and retaining 575,100 shares valued at approximately $39.4 million. Despite the reduction, Cooper Companies reported strong quarterly earnings, beating EPS expectations with a 6.2% increase in revenue. Analysts generally maintain a "Moderate Buy" rating for the stock, with a consensus price target of $90.79.
How Is West Pharmaceutical's Stock Performance Compared to Other Healthcare Stocks?
West Pharmaceutical Services (WST) is a large-cap healthcare company with a market cap of $16.6 billion, specializing in containment and delivery systems for injectable drugs. Despite recent stock underperformance—down 27.9% from its 52-week high and lagging behind the XLV ETF year-to-date—the company reported strong Q4 2025 results and issued positive 2026 guidance. Analysts maintain a "Strong Buy" consensus with a significant upside to the current price.
A Look At Cooper Companies (COO) Valuation After Recent Share Price Weakness
Cooper Companies (COO) has experienced recent share price weakness, leading investors to re-evaluate its valuation. Despite the current price of US$71.52, the company is considered undervalued with a narrative fair value of $91.25, supported by improving free cash flow projections. However, its P/E ratio of 34.8x is higher than the industry average, posing a potential valuation risk if growth or margins fall short.
A Look At Cooper Companies (COO) Valuation After Recent Share Price Weakness
Cooper Companies (COO) has experienced recent stock price weakness, prompting a reassessment of its valuation. Despite the pullback, Simply Wall St's analysis suggests the stock is currently undervalued with a fair value of $91.25 against its current price of $71.52, supported by improving free cash flow expectations. However, investors should consider potential valuation risk due to its higher P/E ratio compared to industry averages and the need for strong future growth and margins to support the narrative.
Here’s Why Including Merit Medical Shares in Your Investment Portfolio Makes Sense Now
Merit Medical Systems, Inc. (MMSI) is poised for continued growth driven by its strong medical device pipeline, particularly in cardiovascular and therapeutic products, and strategic acquisitions. Despite recent stock drops and challenges like tariffs and economic pressures in China, analysts are optimistic about its future earnings. The company anticipates a 9.5% growth rate over the next five years, supported by innovation and expanding global procedure volumes.
Schroder Investment Management Group Has $41.94 Million Holdings in The Cooper Companies, Inc. $COO
Schroder Investment Management Group has reported a 19.1% reduction in its stake in The Cooper Companies, Inc. (NASDAQ:COO) during the third quarter, reducing its holdings to 619,816 shares valued at $41.94 million. Other institutional investors also adjusted their positions in the medical device company, while company insiders acquired a significant number of shares. Analysts currently rate Cooper Companies with a "Moderate Buy" consensus and an average target price of $90.79.
